Publications:

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer.

Cancers

Collins, Denis M DM; Conlon, Neil T NT; Kannan, Srinivasaraghavan S; Verma, Chandra S CS; Eli, Lisa D LD; Lalani, Alshad S AS; Crown, John J

Publication Date: 2019-05-28

Variant appearance in text: HER2: K676R

PubMed Link: 31141894

Variant Present in the following documents:

• Main text

View BVdb publication page

Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice.

Plos One

Prentice, Leah M LM; Miller, Ruth R RR; Knaggs, Jeff J; Mazloomian, Alborz A; Aguirre Hernandez, Rosalia R; Franchini, Patrick P; Parsa, Kourosh K; Tessier-Cloutier, Basile B; Lapuk, Anna A; Huntsman, David D; Schaeffer, David F DF; Sheffield, Brandon S BS

Publication Date: 2018

Variant appearance in text: ERBB2: K676R

PubMed Link: 29698444

Variant Present in the following documents:

• pone.0196434.s001.xlsx, sheet 2
• pone.0196434.s001.xlsx, sheet 3
• pone.0196434.s001.xlsx, sheet 1

View BVdb publication page